| Aspirin (NSAID) |
Meloxicam (NSAID) |
44-Fold increase in pH 7.4 phosphate buffer solubility with improved bioavailability and Cmax
|
2011 |
195
|
| Sildenafil (erectile dysfunction) |
Enhanced IDR |
2014 |
196
|
| Apremilast (antipsoriatic) |
Increased IDR and solubility |
2018 |
68
|
| Theophylline (antiasthmatic) |
No evaluation of pharmaceutical properties |
2018 |
197
|
| Carbamazepine (antiepileptic) |
No evaluation of pharmaceutical properties |
2019 |
198
|
| Salicylic acid (NSAID) |
Nevirapine (antiretroviral) |
Increased IDR and solubility |
2012 |
199
|
| Piroxicam (NSAID) |
No evaluation of pharmaceutical properties |
2012 |
200
|
| Tenoxicam (NSAID) |
Increased IDR |
2013 |
201
|
| Andrographolide (antiviral) |
Increased solubility, faster dissolution rate, higher drug release |
2013 |
202
|
| Trospium chloride (antispasmodic) |
No evaluation of pharmaceutical properties |
2014 |
203
|
| Ethionamide (antitubercular) |
Enhanced IDR |
2020 |
204
|
| Nicotinamide (skin restorative) |
Mefenamic acid (NSAID) |
No evaluation of pharmaceutical properties |
2011 |
205
|
| Naproxen (NSAID) |
Increased IDR |
2012 |
206
|
| Indomethacin (NSAID) |
No evaluation of pharmaceutical properties |
2013 |
207
|
| Acemetacin (NSAID) |
Increased solubility |
2014 |
208
|
| Celecoxib (NSAID) |
No evaluation of pharmaceutical properties |
2017 |
209
|
| Ibuprofen (NSAID) |
Increased solubility and in vivo analgesic effect |
2018 |
210
|
| Curcumin (NSAID) |
Increased IDR and antinociceptive/anti-inflammatory potency |
2019 |
211
|
| Theophylline (antiasthmatic) |
Diflunisal and diclofenac (NSAID) |
Increased solubility |
2014 |
212
|
| Flufenamic acid (NSAID) |
Increased solubility and hygroscopic stability |
2016 |
213
|
| Aceclofenac (NSAID) |
Paracetamol (analgesic) |
Increased dissolution rate |
2011 |
214
|
| Indomethacin (NSAID) |
Carbamazepine (antiepileptic) |
No evaluation of pharmaceutical properties |
2011 |
215
|
| Flufenamic acid(NSAID) |
Ethenzamide (NSAID) |
Increased solubility |
2017 |
216
|
| Tramadol (NSAID) |
Celecoxib (NSAID) |
Optimized solubility and IDR, improved Cmax and bioavailability |
2017 |
32
|
| Ibuprofen (NSAID) |
Levetiracetam (antiepileptic) |
Chiral resolution |
2018 |
217
|
| Piroxicam (NSAID) |
Clonixin (NSAID) |
Enhanced hydration stability |
2019 |
122
|
| Metacetamol (NSAID) |
Levofloxacin (antibacterial) |
Improved hygroscopic and photostability of levofloxacin |
2019 |
218
|
